Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyHoward I. Scher, Charles L. Sawyers, Mary‐Ellen Taplin et al.|The Lancet|2010Cited by 1.1k
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancerJorge A. Carrasquillo, Michael J. Morris, Joseph A. O’Donoghue et al.|European Journal of Nuclear Medicine and Molecular Imaging|2013Cited by 182